KRAS and non-small cell lung carcinoma: A collection of co-occurring mutations alongside driver mutations plays a significant role in tumor heterogeneity.140 These comutations can markedly affect KRAS function and influence tumor development and progression.74 A study analyzing NSCLC samples (n = 1078) bearing KRAS mutations revealed that 53.3% of these patients also had comutation, with TP53 being the most common (39.4%).